With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.223671-15-6,7-Bromoisoquinolin-1-ol,as a common compound, the synthetic route is as follows.
A suspension [OF 7-BROMO-1-HYDROXYISOQUINOLINE] (7.02g, 28. [2MMOL)] in dimethylformamide [(75ML)] was treated with 4-bromomethylbenzoic acid tert- butyl ester (12.5g, 36.7mmol) and cesium carbonate [(11.] 94g, 36.7mmol), then stirred overnight at room temperature. The dimethylformamide was evaporated in vacuo, the residue diluted with ethyl acetate, washed with IN HC1, the organic portion washed with brine, dried over [MGS04] and evaporated to dryness. The residue was triturated with hot hexanes/ethyl acetate, cooled to room temperature, and the solid collected by filtration and dried to give 8.77g of the product as white crystals (75.7% yield). [1H-NMR] [(CDC13)] ; d 8.58 (d, 1H), 7.95-7. 93 (d, 2H), 7.73-7. 71 (dd, 1H), 7.39- 7.32 (m, [3H),] 7.07-7. 05 (d, [1H),] 6.46-6. 44 (d, 1H), 5.24 (s, [2H),] 1.57 (s, 9H). MS: [M+ +1] = 414.0/416. 0 Da
223671-15-6, As the paragraph descriping shows that 223671-15-6 is playing an increasingly important role.
Reference：
Patent; WARNER-LAMBERT COMPANY LLC; WO2004/14379; (2004); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem